CHAPTER 14. MRM-based Protein Quantification with Labeled Standards for Biomarker Discovery, Verification, and Validation in Human Plasma

Author(s):  
Andrew J. Percy ◽  
Andrew G. Chambers ◽  
Carol E. Parker ◽  
Christoph H. Borchers
2011 ◽  
Vol 4 ◽  
pp. PRI.S6470
Author(s):  
Sandra Sénéchal ◽  
Martin Kussmann

Blood serum is a body fluid widely used for biomarker discovery and therefore numerous studies aim at defining its proteome. The serum proteome is subject to fluctuations resulting from biological variability (eg, diurnal variations) reflecting both healthy and/or disease-related conditions. Inter-individual differences originate partly at the genetic level and may influence clinical blood profile including the serum proteome. Therefore we investigated whether serum protein abundance is genetically determined: we report the study of a cohort of 146 Portuguese Water Dogs, a dog breed whose genetic background has been well characterized. We generated protein profiles of dog sera on 1D-gels and correlated them with microsatellite markers. We detected correlations between 7 gel bands and 11 genetic regions and developed a label-free protein quantification method to identify and quantify the proteins most accountable for serum proteome variation. An association between the abundance of RBP4 in dog serum and the adiponectin gene was detected.


2013 ◽  
Vol 59 (1) ◽  
pp. 315-324 ◽  
Author(s):  
Danni Li ◽  
Hanching Chiu ◽  
Jing Chen ◽  
Hui Zhang ◽  
Daniel W Chan

BACKGROUND Well-annotated clinical samples are valuable resources for biomarker discovery and validation. Multiplex and integrated methods that simultaneously measure multiple analytes and generate integrated information about these analytes from a single measurement are desirable because these methods help conserve precious samples. We developed a magnetic bead–based system for multiplex and integrated glycoprotein quantification by immunoassays and glycan detection by lectin immunosorbent assays (LISAs). METHODS Magnetic beads coupled with antibodies were used for capturing proteins of interest. Biotinylated antibodies in combination with streptavidin-labeled phycoerythrin were used for protein quantification. In the LISAs, biotinylated detection antibodies were replaced by biotinylated lectins for glycan detection. RESULTS Using tissue inhibitor of metallopeptidase 1 (TIMP-1), tissue plasminogen activator, membrane metallo-endopeptidase, and dipeptidyl peptidase-IV (DPP-4) as models, we found that the multiplex integrated system was comparable to single immunoassays in protein quantification and LISAs in glycan detection. The merits of this system were demonstrated when applied to well-annotated prostate cancer tissues for validation of biomarkers in aggressive prostate cancer. Because of the system's multiplex ability, we used only 300 ng of tissue protein for the integrated detection of glycans in these proteins. Fucosylated TIMP-1 and DPP-4 offered improved performance over the proteins in distinguishing aggressive and nonaggressive prostate cancer. CONCLUSIONS The multiplex and integrated system conserves samples and is a useful tool for validation of glycoproteins and their glycoforms as biomarkers.


2012 ◽  
Vol 11 (4) ◽  
pp. 2103-2113 ◽  
Author(s):  
Cong Zhou ◽  
Kathryn L. Simpson ◽  
Lee J. Lancashire ◽  
Michael J. Walker ◽  
Martin J. Dawson ◽  
...  

2020 ◽  
Author(s):  
Rodosthenis S. Rodosthenous ◽  
Elizabeth Hutchins ◽  
Rebecca Reiman ◽  
Ashish S. Yeri ◽  
Srimeenakshi Srinivasan ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Monika Dzieciatkowska ◽  
Guihong Qi ◽  
Jinsam You ◽  
Kerry G. Bemis ◽  
Heather Sahm ◽  
...  

Cerebrospinal fluid (CSF) has been used for biomarker discovery of neurodegenerative diseases in humans since biological changes in the brain can be seen in this biofluid. Inactivation of A-T-mutated protein (ATM), a multifunctional protein kinase, is responsible for A-T, yet biochemical studies have not succeeded in conclusively identifying the molecular mechanism(s) underlying the neurodegeneration seen in A-T patients or the proteins that can be used as biomarkers for neurologic assessment of A-T or as potential therapeutic targets. In this study, we applied a high-throughput LC/MS-based label-free protein quantification technology to quantitatively characterize the proteins in CSF samples in order to identify differentially expressed proteins that can serve as potential biomarker candidates for A-T. Among 204 identified CSF proteins with high peptide-identification confidence, thirteen showed significant protein expression changes. Bioinformatic analysis revealed that these 13 proteins are either involved in neurodegenerative disorders or cancer. Future molecular and functional characterization of these proteins would provide more insights into the potential therapeutic targets for the treatment of A-T and the biomarkers that can be used to monitor or predict A-T disease progression. Clinical validation studies are required before any of these proteins can be developed into clinically useful biomarkers.


iScience ◽  
2020 ◽  
Vol 23 (6) ◽  
pp. 101182
Author(s):  
Rodosthenis S. Rodosthenous ◽  
Elizabeth Hutchins ◽  
Rebecca Reiman ◽  
Ashish S. Yeri ◽  
Srimeenakshi Srinivasan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document